Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Mayo Clin, Jacksonville, FL USA
[4] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页码：TPS283 / TPS283
页数：1
相关论文
共 50 条
  • [31] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)
    Hollebecque, Antoine
    Calvo, Aitana
    Andre, Thierry
    Argiles, Guillem
    Cervantes, Andres
    Leger, Catherine
    Valette, Aude
    Amellal, Nadia
    Fougeray, Ronan
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress
    Kato, T.
    Satake, H.
    Oba, K.
    Kagawa, Y.
    Yasui, H.
    Nakamura, M.
    Watanabe, T.
    Matsumoto, T.
    Hirata, K.
    Muro, K.
    Komatsu, Y.
    Yoshino, T.
    Yamazaki, K.
    Mishima, H.
    Kotaka, M.
    Tsuji, A.
    Kakeji, Y.
    Oki, E.
    Nagata, N.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 83 - 83
  • [34] MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
    Strickler, John H.
    Ng, Kimmie
    Cercek, Andrea
    Fountzilas, Christos
    Sanchez, Federico Augusto
    Hubbard, Joleen M.
    Wu, Christina
    Siena, Salvatore
    Tabernero, Josep
    Van Cutsem, Eric
    Kardosh, Adel
    Saeed, Anwaar
    Andre, Thierry
    Stecher, Michael
    Palanca-Wessels, Maria Corinna
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [35] A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
    Shin, Sang Joon
    Lee, Jeeyun
    Chung, Ik-Joo
    Kim, Tae Won
    Chun, Hoo Geun
    Shin, Dongbok
    Kim, Yeul Hong
    Song, Hong-Suk
    Han, Sae-Won
    Kim, Jong Gwang
    Kim, Sun Young
    Choi, Young Jin
    Chung, Hyun Cheol
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
    Jeeyun Lee
    Sang Joon Shin
    Ik Joo Chung
    Tae Won Kim
    Hoo-Geun Chun
    Dong Bok Shin
    Yeul Hong Kim
    Hong Suk Song
    Sae-Won Han
    Jong Gwang Kim
    Sun Young Kim
    Young Jin Choi
    Hyun Cheol Chung
    Investigational New Drugs, 2014, 32 : 561 - 568
  • [37] A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
    Lee, Jeeyun
    Shin, Sang Joon
    Chung, Ik Joo
    Kim, Tae Won
    Chun, Hoo-Geun
    Shin, Dong Bok
    Kim, Yeul Hong
    Song, Hong Suk
    Han, Sae-Won
    Kim, Jong Gwang
    Kim, Sun Young
    Choi, Young Jin
    Chung, Hyun Cheol
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 561 - 568
  • [38] Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
    Le, Dung T.
    Kim, Tae Won
    Van Cutsem, Eric
    Geva, Ravit
    Jager, Dirk
    Hara, Hiroki
    Burge, Matthew
    O'Neil, Bert
    Kavan, Petr
    Yoshino, Takayuki
    Guimbaud, Rosine
    Taniguchi, Hiroya
    Elez, Elena
    Al-Batran, Salah-Eddin
    Boland, Patrick M.
    Crocenzi, Todd
    Atreya, Chloe E.
    Cui, Yi
    Dai, Tong
    Marinello, Patricia
    Diaz, Luis A., Jr.
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 11 - +
  • [39] Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).
    Lentz, Robert William
    Hu, Junxiao
    Blatchford, Patrick Jud
    Pitts, Todd
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Lieu, Christopher Hanyoung
    Scott, Aaron James
    Boland, Patrick M.
    Hochster, Howard S.
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS257 - TPS257
  • [40] Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
    Xu, Yun
    Wu, Yuchen
    Dai, Yuedi
    Ji, Xiaopin
    Cui, Zhe
    Zhu, Xiaodong
    Xu, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 151 - 151
12345